Abingworth LLP - 13 May 2021 Form 4 Insider Report for Vera Therapeutics, Inc. (VERA)

Reporting relationship: 10%+ Owner
Issuer ticker: VERA
Reported as of: 13 May 2021
Net transaction value: +$8,499,997
SEC form: 4
Accepted by SEC: 18 May 2021, 18:00:19 UTC
Prior SEC filing: 31 Mar 2022
Next SEC filing: 27 Aug 2021
Source filing: View source filing
Reporting owner signature: /s/ John Heard

Key filing fact

Abingworth LLP filed Form 4 for Vera Therapeutics, Inc. (VERA) on 18 May 2021.

Key facts

This page summarizes Abingworth LLP's Form 4 filing for Vera Therapeutics, Inc. (VERA).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 18 May 2021, 18:00.

Change

Previous filing in this sequence was filed on 31 Mar 2022.
Current net transaction value: +$8,499,997.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VERA transaction

Class A Common Stock

Conversion of derivative security

Transaction value
Shares: +2,187,504
Change %
Price
Shares after: 2,187,504
Date: 18 May 2021
Ownership: See Footnote
Footnotes: F1, F2

VERA transaction

Class A Common Stock

Purchase

Transaction value: $8,499,997
Shares: +772,727
Change %: +35%
Price: $11.00
Shares after: 2,960,231
Date: 18 May 2021
Ownership: See Footnote
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VERA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +9,925
Change %
Price: $0.000000
Shares after: 9,925
Date: 13 May 2021
Ownership: See footnotes
Underlying class: Class A Common Stock
Underlying amount: 9,925
Exercise price: $11.00
Footnotes: F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

Footnote F2

The shares are held by Abingworth Bioventures 8 LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. Abingworth LLP disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F3

The options (the "Options") will vest on the earlier of May 13, 2022 or the 2022 annual meeting of stockholders. The Options were granted to Kurt Von Emster ("Von Emster"), a member of Abingworth LLP. Abingworth LLP provides advisory services to ABV 8. Under an agreement between Von Emster and Abingworth LLP, Von Emster is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV 8, and must exercise the Option solely upon the direction of Abingworth LLP.

Footnote F4

ABV 8 may be deemed the indirect beneficial owner of the Option, and Von Emster may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV 8. Abingworth LLP disclaims beneficial ownership of the Option except to the extent, if any, of its pecuniary interest therein. This report shall not be deemed an admission that Abingworth LLP, ABV 8, Von Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.